FundMyPitch
Pre Seed Round in 2025
Fundmypitch is a platform that bridges the gap between angel investors and businesses seeking investment. They provide a transparent and ultra-secure environment for investors and entrepreneurs to interact and connect.
Neurovalens
Funding Round in 2024
Neurovalens is a UK-based company founded in 2013 that specializes in developing medical devices grounded in neuroscience, bioscience, and neurophysiology. The company's portfolio includes Stimu Slim and Modius, electronic headsets designed to address obesity through non-invasive neurostimulation. Neurovalens' technology focuses on transdermal activation of key brain regions to modulate autonomic function, circadian rhythms, and metabolic processes, offering healthcare providers drug-free treatment options for various health conditions. The company has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme to enhance its research and development activities.
GoPlugable is a pioneering startup that connects electric vehicle (EV) drivers with private, slow-charging points in homes and businesses via a user-friendly mobile app. The company's peer-to-peer platform enables EV drivers without access to home charging to book and pay for charging sessions, while hosts can monetize their idle chargers and businesses can enhance customer experience and sustainability efforts. With a focus on slow charging, GoPlugable differentiates itself from major providers and has secured strategic partnerships with brands like Ohme and SSE Airtricity. As of 2024, the platform has over 1,200 downloads and has achieved notable growth with 120 host users and 450 chargee users, demonstrating its potential in the expanding EV charging market.
CV6 Therapeutics
Venture Round in 2022
CV6 Therapeutics is a drug development company dedicated to discovering, developing, and commercializing innovative therapies for human diseases, with a particular focus on cancer and inflammatory conditions. The company specializes in analyzing cancer cells to identify novel drug targets that leverage specific vulnerabilities in these cells. By addressing the challenges of chemotherapy resistance, CV6 Therapeutics aims to facilitate the development of effective therapeutics that enhance patient outcomes in the treatment of cancer and inflammatory diseases.
CV6 Therapeutics
Grant in 2022
CV6 Therapeutics is a drug development company dedicated to discovering, developing, and commercializing innovative therapies for human diseases, with a particular focus on cancer and inflammatory conditions. The company specializes in analyzing cancer cells to identify novel drug targets that leverage specific vulnerabilities in these cells. By addressing the challenges of chemotherapy resistance, CV6 Therapeutics aims to facilitate the development of effective therapeutics that enhance patient outcomes in the treatment of cancer and inflammatory diseases.
TruCorp is a manufacturer and distributor specializing in the design and production of training manikins for medical professionals. The company offers a diverse range of products aimed at enhancing airway management, trauma training, ultrasound, and procedural skills for both adults and pediatric patients. TruCorp's training manikins are anatomically accurate and are used for comprehensive CPR and AED training, among other applications. By focusing on continuous innovation and refinement, TruCorp provides healthcare professionals with realistic medical simulators that improve medical skill training and enhance patient safety. The company's commitment to advancing medical education ultimately aims to increase educational efficiency and contribute to better health outcomes.
Signum Surgical
Venture Round in 2022
Signum Surgical Limited is a medical technology company based in Galway, Ireland, founded in 2014 by Eoin Bambury and Moshe Zilversmit. The company specializes in developing innovative solutions for the treatment of perianal fistulas, which are small tunnels that form between the end of the bowel and the skin near the anus. Signum Surgical's primary product is a bio-absorbable implant designed to be used post-surgery, facilitating the closure and healing of the fistula tract. This implant dissolves within the body after treatment and helps prevent reinfection, thereby promoting a faster healing process. The company's focus on addressing the lack of innovation in this area aims to enhance the effectiveness of care for patients suffering from colorectal conditions.
Neurovalens is a UK-based company founded in 2013 that specializes in developing medical devices grounded in neuroscience, bioscience, and neurophysiology. The company's portfolio includes Stimu Slim and Modius, electronic headsets designed to address obesity through non-invasive neurostimulation. Neurovalens' technology focuses on transdermal activation of key brain regions to modulate autonomic function, circadian rhythms, and metabolic processes, offering healthcare providers drug-free treatment options for various health conditions. The company has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme to enhance its research and development activities.
Ogletree Deakins
Grant in 2021
Ogletree Deakins is a labor and employment law firm representing management in all types of employment. It represents employers of all sizes and across many industries, from small businesses to Fortune 500 companies.
Konvi
Convertible Note in 2021
Konvi is a European crowdfunding platform that facilitates partial ownership of high-yielding luxury assets. The platform allows users to invest in rare and valuable goods, offering greater potential for value appreciation compared to traditional asset classes. By enabling portfolio diversification through access to these exclusive assets, Konvi connects investors with industry experts and luxury funds globally. This approach provides a unique opportunity for individuals to gain exposure to lucrative investment options within the luxury market.
Globus
Venture Round in 2020
Globus.ai is an innovative company in the staffing and recruitment sector, established in 2017. It offers an AI-powered software-as-a-service platform that enhances the efficiency of recruiters and candidates by automating and streamlining the staffing process. The platform specializes in engaging and activating existing candidates, managing incoming job requests, placing candidates, and delivering actionable business insights. By leveraging advanced AI technology, Globus aims to redefine the staffing industry, enabling recruiters to place candidates more effectively and rapidly while maximizing the potential of their talent pools.
Gratsi
Pre Seed Round in 2020
Gratsi is a technology company that develops a secure, contactless payment platform for exchanging gratuities and tips in the hospitality and food service sectors. Its platform facilitates digital, encrypted payments, eliminating the need for cash handling by both customers and employees.
Centre for Advanced Sustainable Energy
Venture Round in 2020
The Centre for Advanced Sustainable Energy (CASE) is an industry-led sustainable energy research centre. Through the Invest Northern Ireland Competence Centre programme they fund collaborative Research & Development (R&D) in sustainable energy. They bridge the gap between industry research needs and academic research offerings.
Armstrong Medical
Venture Round in 2020
Armstrong Medical is a UK-based manufacturer specializing in high-quality innovative products for anaesthesia, respiratory care, and critical care applications. The company focuses on developing respiratory consumables that cater to perioperative and neonatal needs. Its products are designed to support patients with lung injuries, particularly in critical situations such as bomb blast incidents. By providing disposable respiratory products, Armstrong Medical aims to enhance the efficacy of healthcare providers in delivering essential care during emergencies and complex medical procedures.
We Are Paradoxx
Seed Round in 2019
We Are Paradoxx is a haircare brand dedicated to environmental and social responsibility, offering a range of products that are 90% plastic-free and entirely free from toxins, irritants, and synthetic fragrances. The company emphasizes ethical and organic formulations, utilizing green chemistry to create vegan products that appeal to eco-conscious consumers. By providing multi-tasking haircare solutions, We Are Paradoxx aims to make sustainable and eco-friendly beauty accessible to all individuals, promoting an environmentally friendly haircare experience.
We Are Paradoxx
Seed Round in 2019
We Are Paradoxx is a haircare brand dedicated to environmental and social responsibility, offering a range of products that are 90% plastic-free and entirely free from toxins, irritants, and synthetic fragrances. The company emphasizes ethical and organic formulations, utilizing green chemistry to create vegan products that appeal to eco-conscious consumers. By providing multi-tasking haircare solutions, We Are Paradoxx aims to make sustainable and eco-friendly beauty accessible to all individuals, promoting an environmentally friendly haircare experience.
Kainos WorkSmart
Venture Round in 2018
Established in 1986 as a joint venture between Fujitsu and Queen’s University Belfast, Kainos has become an international company with offices across the UK, Europe and the USA. And they continue to grow rapidly and fluidly. Throughout, and beyond their industry expertise, their success has been driven by consistently delivering for their customers. They do that by being accessible, collaborative and creative, and by hiring and investing in the best talent. They have always hired the best people they can find, given them challenging work they can cut their teeth on, and driven their development.
SiSaf Ltd. is a biopharmaceutical and drug delivery company based in Guildford, United Kingdom, specializing in RNA delivery and therapeutics. Founded in 2006, the company utilizes its proprietary Bio-Courier technology, which combines organic materials with bioabsorbable silicon, to enhance the stability, safety, and efficiency of RNA therapeutics. SiSaf's portfolio includes silicon-stabilized hybrid lipid nanoparticles designed to address rare genetic disorders, particularly autosomal dominant conditions. The company also offers formulation services and licenses its innovative technologies to clients in various scientific sectors, including pharmaceuticals and biotechnology. With fully integrated research labs and a growing patent estate, SiSaf is positioned to advance its drug development capabilities through strategic partnerships and collaborations, notably with Avellino Labs USA and Croda International.
Fusion Antibodies
Grant in 2018
Fusion Antibodies plc is a contract research organization based in Belfast, United Kingdom, specializing in the research, development, and manufacture of recombinant proteins and antibodies, particularly for cancer and infectious diseases. The company provides a comprehensive suite of services, including monoclonal antibody discovery and development, antibody engineering, humanization, affinity maturation, and antibody reformatting. Additionally, its offerings encompass antibody sequencing, custom expression and purification of recombinant proteins, transient protein expression, and cell line development. Fusion Antibodies operates on a fee-for-service basis, tailoring its services to meet the specific needs of pharmaceuticals, biotechnology, and diagnostic companies. Established in 2000, the company has built strong partnerships globally, enhancing its ability to deliver high-quality solutions. Its expertise in producing fully humanized monoclonal antibodies is critical for advancing drug development to clinical stages.
BrainWaveBank
Grant in 2018
BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.
ProtectBox
Seed Round in 2017
ProtectBox is a cybersecurity comparison marketplace aimed at making cybersecurity accessible for small and medium-sized businesses. It utilizes a proprietary decision-making AI to assess the security risk position of users and offers individualized bundles of solutions to mitigate these risks. The platform allows users to input their cybersecurity needs, which the AI analyzes to generate a customized suite of security products and services. ProtectBox emphasizes sustainability by incorporating ratings and reviews that help offset the carbon impact of purchases. Additionally, it features intelligent chatbots that support multilingual interaction, enabling users to communicate through various devices and platforms. Overall, ProtectBox focuses on providing a smarter, greener, and safer approach to cybersecurity solutions.
Ampliphae
Seed Round in 2016
Ampliphae Ltd, established in 2015 and headquartered in Belfast, UK, specializes in cloud management solutions. It offers a suite of services including cloud application discovery, real-time trend reporting, proactive cloud governance, data privacy compliance, and cloud control. The company's platform uses artificial intelligence and machine learning to identify and mitigate risks associated with the use of Software as a Service (SaaS) applications within organizations. It also provides a database of SaaS applications and manages Bring Your Own Device (BYOD) cloud risks.
SiSaf Ltd. is a biopharmaceutical and drug delivery company based in Guildford, United Kingdom, specializing in RNA delivery and therapeutics. Founded in 2006, the company utilizes its proprietary Bio-Courier technology, which combines organic materials with bioabsorbable silicon, to enhance the stability, safety, and efficiency of RNA therapeutics. SiSaf's portfolio includes silicon-stabilized hybrid lipid nanoparticles designed to address rare genetic disorders, particularly autosomal dominant conditions. The company also offers formulation services and licenses its innovative technologies to clients in various scientific sectors, including pharmaceuticals and biotechnology. With fully integrated research labs and a growing patent estate, SiSaf is positioned to advance its drug development capabilities through strategic partnerships and collaborations, notably with Avellino Labs USA and Croda International.
Revel Systems
Grant in 2014
Revel Systems, Inc. is a manufacturer and distributor of cloud-based point of sale (POS) and business management solutions. Founded in 2010 and headquartered in Atlanta, Georgia, with additional offices in locations such as San Francisco, Lithuania, Singapore, Australia, and London, the company provides a comprehensive platform that integrates POS software with essential management tools. Its offerings include Revel Essential for small chains and merchants, and Revel Enterprise, designed for larger chains and global enterprises. The platform features capabilities such as inventory management, employee management, integrated payroll, and customer relationship management, all accessible through iOS-based technology on iPads. Revel Systems serves a diverse range of industries, including restaurants, retail, grocery, and service sectors, enabling clients to enhance their operations, improve customer experience, and streamline business processes.
SiSaf Ltd. is a biopharmaceutical and drug delivery company based in Guildford, United Kingdom, specializing in RNA delivery and therapeutics. Founded in 2006, the company utilizes its proprietary Bio-Courier technology, which combines organic materials with bioabsorbable silicon, to enhance the stability, safety, and efficiency of RNA therapeutics. SiSaf's portfolio includes silicon-stabilized hybrid lipid nanoparticles designed to address rare genetic disorders, particularly autosomal dominant conditions. The company also offers formulation services and licenses its innovative technologies to clients in various scientific sectors, including pharmaceuticals and biotechnology. With fully integrated research labs and a growing patent estate, SiSaf is positioned to advance its drug development capabilities through strategic partnerships and collaborations, notably with Avellino Labs USA and Croda International.
Taggled
Seed Round in 2014
Taggled is an innovative online video commerce platform that allows both personal and business users to create interactive and shoppable videos. The platform utilizes drag-and-drop technology, enabling video creators to seamlessly add clickable tags for products, people, places, and music within their content. This unique approach to shoppable video has resulted in impressive conversion rates for account holders, ranging from 1% to 5%. Taggled caters to a diverse clientele, including video bloggers, performance marketing firms, brands, and retailers. Notably, it is recognized as the only Twitter Approved provider of shoppable online videos, enhancing the social shopping experience for users.
FD Technologies
Post in 2010
FD Technologies is a prominent provider of data-driven products and consulting services, catering primarily to major financial, technology, and energy institutions. The company is best known for developing kdb+, a leading database technology that addresses complex data management and analytics challenges. Established in 1996, FD Technologies specializes in delivering mission-critical data and trading systems that support front, middle, and back-office operations, particularly for financial institutions engaged in high-volume trading across various asset classes such as equities, fixed income, and foreign exchange. In addition to its core focus on capital markets, the company extends its expertise to other sectors, including telecoms, digital marketing, pharmaceuticals, and utilities. With a strong presence in the Americas and additional operations in the UK, EMEA, and Asia Pacific, FD Technologies combines deep domain knowledge with technical proficiency in leading financial services systems to help clients navigate the complexities of an increasingly regulated market.
Intune Networks
Venture Round in 2009
Intune Networks is a developer of innovative optical switching systems aimed at enhancing telecommunications infrastructure. The company has created a groundbreaking networking technology that enables telecom operators to construct simpler, more efficient networks with significantly improved connectivity. By utilizing tuneable lasers and the emerging Optical Burst Switching (OBS) standard, Intune's optical Ethernet switch fabric allows real-time packet switching over long distances, spanning hundreds of kilometers. This approach not only simplifies network complexity but also minimizes the number of required components, enabling instant bandwidth availability at any point within the network. Intune's solutions are designed to help carriers virtualize connectivity and transform mobile transport networks, positioning the company as a key player in the telecommunications sector.
SiSaf
Pre Seed Round in 2008
SiSaf Ltd. is a biopharmaceutical and drug delivery company based in Guildford, United Kingdom, specializing in RNA delivery and therapeutics. Founded in 2006, the company utilizes its proprietary Bio-Courier technology, which combines organic materials with bioabsorbable silicon, to enhance the stability, safety, and efficiency of RNA therapeutics. SiSaf's portfolio includes silicon-stabilized hybrid lipid nanoparticles designed to address rare genetic disorders, particularly autosomal dominant conditions. The company also offers formulation services and licenses its innovative technologies to clients in various scientific sectors, including pharmaceuticals and biotechnology. With fully integrated research labs and a growing patent estate, SiSaf is positioned to advance its drug development capabilities through strategic partnerships and collaborations, notably with Avellino Labs USA and Croda International.
Fusion Antibodies
Venture Round in 2007
Fusion Antibodies plc is a contract research organization based in Belfast, United Kingdom, specializing in the research, development, and manufacture of recombinant proteins and antibodies, particularly for cancer and infectious diseases. The company provides a comprehensive suite of services, including monoclonal antibody discovery and development, antibody engineering, humanization, affinity maturation, and antibody reformatting. Additionally, its offerings encompass antibody sequencing, custom expression and purification of recombinant proteins, transient protein expression, and cell line development. Fusion Antibodies operates on a fee-for-service basis, tailoring its services to meet the specific needs of pharmaceuticals, biotechnology, and diagnostic companies. Established in 2000, the company has built strong partnerships globally, enhancing its ability to deliver high-quality solutions. Its expertise in producing fully humanized monoclonal antibodies is critical for advancing drug development to clinical stages.
Axis Three
Venture Round in 2006
Axis Three specializes in developing and distributing advanced 3D surgical simulation tools tailored specifically for the cosmetic surgery market. Leveraging a strategic partnership with Siemens and proprietary physics-driven tissue typing software, Axis Three aims to set new industry standards by offering predictive simulations that enable patients to visualize their post-surgery appearance using their own body scans.
Avalon Instruments
Venture Round in 2005
Avalon is a developer, manufacturer and seller of scientific analytical instrumentation based on Raman spectroscopy techniques.
Gendel
Venture Round in 2005
Gendel has developed a unique, proprietary platform technology for the localised delivery of biological molecules to target sites within the body. Biopharmaceuticals may be loaded into the body's own natural carrier system by a physical process and released at the target site in response to the application of non-invasive, low intensity ultrasound. Gendel's technology may be employed for the delivery of a range of biological payloads including antibodies, enzymes, peptides, olionucleotides and DNA as well as carrier peptides and gene therapy vectors.
Aepona Limited is a technology company headquartered in Belfast, United Kingdom, that specializes in providing a platform for business transformation tailored for telecommunications operators and enterprises. Founded in 1995, Aepona enables organizations to leverage their data, connected devices, and infrastructure by creating and monetizing services through managed APIs. Its offerings include an API monetization platform designed for communications service providers, a service creation and orchestration solution that incorporates API management, and a payments and settlement engine that facilitates the implementation of diverse business models. Aepona serves a global customer base across Europe, North America, and Southeast Asia, with additional locations in Bristol, United Kingdom; Colombo, Sri Lanka; and Leixlip, Ireland. The company operates as a subsidiary of Persistent Systems, Inc. as of October 2015.
Lagan Technologies
Series B in 2004
Lagan Technologies Ltd. specializes in designing and delivering enterprise case management solutions tailored for government agencies primarily in North America and Europe. The company offers a range of products, including Enterprise Case Management software for government organizations, Lagan 311 for 311 call centers, Lagan Human Services for human services agencies, and a specialized solution for managing Department of Motor Vehicles processes. In addition to its software products, Lagan Technologies provides comprehensive services such as project management, consultancy, installation, testing, integration, education, training, skills transfer, support, and maintenance. Established in 1994 and headquartered in Belfast, United Kingdom, the company also maintains offices in London, Chicago, and Washington, D.C., serving various advocates and councils both in the UK and internationally.
Aepona
Venture Round in 2003
Aepona Limited is a technology company headquartered in Belfast, United Kingdom, that specializes in providing a platform for business transformation tailored for telecommunications operators and enterprises. Founded in 1995, Aepona enables organizations to leverage their data, connected devices, and infrastructure by creating and monetizing services through managed APIs. Its offerings include an API monetization platform designed for communications service providers, a service creation and orchestration solution that incorporates API management, and a payments and settlement engine that facilitates the implementation of diverse business models. Aepona serves a global customer base across Europe, North America, and Southeast Asia, with additional locations in Bristol, United Kingdom; Colombo, Sri Lanka; and Leixlip, Ireland. The company operates as a subsidiary of Persistent Systems, Inc. as of October 2015.